Title: Ibritumomab Tiuxetan
CAS Registry Number: 206181-63-7
CAS Name: Anti-(human CD20 antigen) immunoglobulin G1 (mouse monoclonal IDEC-Y2B8 g1-chain) disulfide with mouse monoclonal IDEC-Y2B8 k-chain, dimer N-[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-N-[2-[bis(carboxymethyl)amino]propyl]glycine conjugate
Literature References: Murine monoclonal antibody targeted against CD-20 antigen on mature B lymphocytes, conjugated to linker-chelator tiuxetan. Radiolabeled form designed for antibody-targeted treatment of non-Hodgkin's lymphoma (NHL). Prepn of monoclonal antibody: M. E. Reff et al., Blood 83, 435 (1994). Prepn of radiolabeled conjugate: D. R. Anderson et al., WO 9411026; eidem, US 5736137 (1994, 1998 both to IDEC); P. C. Chinn et al., Int. J. Oncol. 15, 1017 (1999). Clinical pharmacology: S. J. Knox et al., Clin. Cancer Res. 2, 457 (1996). Clinical evaluation in NHL: T. E. Witzig et al., J. Clin. Oncol. 17, 3793 (1999). Review of development and therapeutic potential: G. A. Wiseman et al., Clin. Cancer Res. 5 Suppl., 3281s-3286s (1999); of clinical experience: A. J. Grillo-López, Expert Rev. Anticancer Ther. 2, 485-493 (2002).
Derivative Type: 90Y-Labeled form
Additional Names: Y2B8-MX-DTPA
Manufacturers' Codes: IDEC-Y2B8
Trademarks: Zevalin (IDEC)
Therap-Cat: 90Y-Labeled form as antineoplastic. |